Laura J Sherrard1, Scott C Bell, Michael M Tunney. 1. aLung Bacteria Group, QIMR Berghofer Medical Research Institute bAdult Cystic Fibrosis Centre, The Prince Charles Hospital cSchool of Medicine, The University of Queensland, Brisbane, Queensland, Australia dCF & Airways Microbiology Group, Queen's University Belfast eSchool of Pharmacy, Queen's University Belfast, Belfast, UK.
Abstract
PURPOSE OF REVIEW: Anaerobic bacteria are not only normal commensals, but are also considered opportunistic pathogens and have been identified as persistent members of the lower airway community in people with cystic fibrosis of all ages and stages of disease. Currently, the role of anaerobic bacteria in cystic fibrosis lower airway disease is not well understood. Therefore, this review describes the recent studies relating to the potential pathophysiological role(s) of anaerobes within the cystic fibrosis lungs. RECENT FINDINGS: The most frequently identified anaerobic bacteria in the lower airways are common to both cystic fibrosis and healthy lungs. Studies have shown that in cystic fibrosis, the relative abundance of anaerobes fluctuates in the lower airways with reduced lung function and increased inflammation associated with a decreased anaerobic load. However, anaerobes found within the lower airways also produce virulence factors, may cause a host inflammatory response and interact synergistically with recognized pathogens. SUMMARY: Anaerobic bacteria are potentially members of the airway microbiota in health but could also contribute to the pathogenesis of lower airway disease in cystic fibrosis via both direct and indirect mechanisms. A personalized treatment strategy that maintains a normal microbial community may be possible in the future.
PURPOSE OF REVIEW: Anaerobic bacteria are not only normal commensals, but are also considered opportunistic pathogens and have been identified as persistent members of the lower airway community in people with cystic fibrosis of all ages and stages of disease. Currently, the role of anaerobic bacteria in cystic fibrosis lower airway disease is not well understood. Therefore, this review describes the recent studies relating to the potential pathophysiological role(s) of anaerobes within the cystic fibrosis lungs. RECENT FINDINGS: The most frequently identified anaerobic bacteria in the lower airways are common to both cystic fibrosis and healthy lungs. Studies have shown that in cystic fibrosis, the relative abundance of anaerobes fluctuates in the lower airways with reduced lung function and increased inflammation associated with a decreased anaerobic load. However, anaerobes found within the lower airways also produce virulence factors, may cause a host inflammatory response and interact synergistically with recognized pathogens. SUMMARY: Anaerobic bacteria are potentially members of the airway microbiota in health but could also contribute to the pathogenesis of lower airway disease in cystic fibrosis via both direct and indirect mechanisms. A personalized treatment strategy that maintains a normal microbial community may be possible in the future.
Authors: Sébastien Boutin; Martin Depner; Mirjam Stahl; Simon Y Graeber; Susanne A Dittrich; Antje Legatzki; Erika von Mutius; Marcus Mall; Alexander H Dalpke Journal: Mediators Inflamm Date: 2017-12-27 Impact factor: 4.711
Authors: Juan de Dios Caballero; Rafael Vida; Marta Cobo; Luis Máiz; Lucrecia Suárez; Javier Galeano; Fernando Baquero; Rafael Cantón; Rosa Del Campo Journal: mBio Date: 2017-09-26 Impact factor: 7.867
Authors: Lisa A Carmody; Lindsay J Caverly; Bridget K Foster; Mary A M Rogers; Linda M Kalikin; Richard H Simon; Donald R VanDevanter; John J LiPuma Journal: PLoS One Date: 2018-03-09 Impact factor: 3.240
Authors: Mehdi Layeghifard; Hannah Li; Pauline W Wang; Sylva L Donaldson; Bryan Coburn; Shawn T Clark; Julio Diaz Caballero; Yu Zhang; D Elizabeth Tullis; Yvonne C W Yau; Valerie Waters; David M Hwang; David S Guttman Journal: NPJ Biofilms Microbiomes Date: 2019-01-21 Impact factor: 7.290
Authors: Ross Pallett; Laura J Leslie; Peter A Lambert; Ivana Milic; Andrew Devitt; Lindsay J Marshall Journal: Sci Rep Date: 2019-05-01 Impact factor: 4.379
Authors: Barry Linnane; Aaron M Walsh; Calum J Walsh; Fiona Crispie; Orla O'Sullivan; Paul D Cotter; Michael McDermott; Julie Renwick; Paul McNally Journal: Microorganisms Date: 2021-02-26
Authors: Jonathan D Cogen; Anna V Faino; Frankline Onchiri; Lucas R Hoffman; Matthew P Kronman; David P Nichols; Margaret Rosenfeld; Ronald L Gibson Journal: Clin Infect Dis Date: 2021-11-02 Impact factor: 20.999
Authors: Michael J Bozzella; Hollis Chaney; Iman Sami; Anastassios Koumbourlis; James E Bost; Edith T Zemanick; Robert J Freishtat; Keith A Crandall; Andrea Hahn Journal: Pediatr Infect Dis J Date: 2021-11-01 Impact factor: 3.806